BridgeBio Pharma Inc. has entered into a significant financial agreement involving the sale of royalty interests. On June 27, 2025, BridgeBio and its subsidiary Eidos Therapeutics, Inc. finalized a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. This agreement involves Eidos selling certain royalty payment rights from net sales of products containing acoramidis in the European Union and related territories. In exchange, the purchasers have agreed to pay Eidos $300 million in cash. The purchasers' rights are capped annually at 60% of royalty payments from Bayer and include an initial hard cap of 145% of the purchase price. This arrangement is secured by specific assets and includes standard representations, warranties, and indemnification obligations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。